Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
143 hedge funds and large institutions have $915M invested in Avidity Biosciences in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 20 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 32
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
9.2% more ownership
Funds ownership: 107.21% → 116.41% (+9.2%)
3% more funds holding
Funds holding: 139 → 143 (+4)
22% less capital invested
Capital invested by funds: $1.17B → $915M (-$251M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
64% less call options, than puts
Call options by funds: $244K | Put options by funds: $674K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$22.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$17.2M |
| 4 |
CAC
Cowen and Company
New York
|
+$13M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$36.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.4M |
| 3 |
CC
Commodore Capital
New York
|
-$9.07M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.67M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
151
Algert Global
San Francisco,
California
| – | -$971K | -63,230 | Closed |
|
152
SG Americas Securities
New York
| – | -$401K | -26,097 | Closed |
|
|
PCM
153
Prelude Capital Management
New York
| – | -$341K | -22,240 | Closed |
|
|
EGM
154
Engineers Gate Manager
New York
| – | -$268K | -17,474 | Closed |
|
|
HS
155
HighVista Strategies
Boston,
Massachusetts
| – | -$257K | -16,733 | Closed |
|
|
XT
156
XTX Topco
George Town,
Cayman Islands
| – | -$198K | -12,919 | Closed |
|
|
SWM
157
Spire Wealth Management
Mclean,
Virginia
| – | -$182K | -11,846 | Closed |
|
|
AA
158
Ancora Advisors
Cleveland,
Ohio
| – | -$92.1K | -6,000 | Closed |
|
|
FFA
159
Farther Finance Advisors
San Francisco,
California
| – | -$7.89K | -514 | Closed |
|
|
TWA
160
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2.89K | -188 | Closed |
|
|
PA
161
Parallel Advisors
San Francisco,
California
| – | -$1.4K | -91 | Closed |
|
|
EI
162
Ellevest Inc
New York
| – | -$230 | -15 | Closed |
|
RNAM Hedge Fund Activity: Q2 2023 in Review
143 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2023, worth a combined $915M — down 22% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RNAM positions and 20 closed out — a net gain of 5 holders — while 64 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $65.3M. The largest seller was Federated Hermes, exiting entirely with an estimated $36.3M sold.
- 143 institutional investors held Avidity Biosciences (RNAM) as of Q2 2023, up from 139 in Q1 2023.
- Funds reported $915M of Avidity Biosciences stock for Q2 2023, down 22% quarter-over-quarter.
- 25 funds opened new Avidity Biosciences positions in Q2 2023 and 20 closed out, a net change of +5 holders.
- The largest Avidity Biosciences buyer in Q2 2023 was Fidelity Investments, an estimated $65.3M added.
- The largest Avidity Biosciences seller in Q2 2023 was Federated Hermes, an estimated $36.3M sold.
Based on aggregated 13F filings for Q2 2023.